clinical trial · NCT07093008
Comparing the Extent to Which AQ280 is Made Available in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation
Eosinophilic EsophagitisAQ280 CapsuleAQ280 Tablet for Oral SuspensionPlacebo CapsulePlacebo Tablet for Oral Suspension
brief summary
This is a Phase 1, investigator- and participant-blinded, placebo-controlled, randomized, crossover study to compare bioavailability of AQ280 following single oral doses of a capsule formulation versus a tablet for oral suspension formulation in healthy participants.
started
Jun 13, 2025
primary completion
Jul 16, 2025
completion
Jul 22, 2025
last updated
Aug 5, 2025
official title
A Phase 1, Investigator- and Participant-blinded, Placebo-Controlled, Randomized, Crossover Study to Assess the Relative Bioavailability of Two Formulations of AQ280 in Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol